| Code | CSB-RA011656MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to itepekimab, targeting interleukin-33 (IL-33), a member of the IL-1 cytokine family that functions as an alarmin released upon cellular stress or tissue damage. IL-33 binds to the ST2 receptor on immune cells, triggering type 2 inflammatory responses involving Th2 cells, eosinophils, and mast cells. This pathway plays a critical role in the pathogenesis of asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and other allergic and inflammatory conditions. Dysregulated IL-33 signaling has also been implicated in fibrotic diseases and certain cancers.
Itepekimab is a human IgG4 monoclonal antibody that neutralizes IL-33 by preventing its interaction with the ST2 receptor, thereby blocking downstream inflammatory cascades. This biosimilar antibody serves as a valuable research tool for investigating IL-33-mediated immune responses, exploring therapeutic mechanisms in type 2 inflammatory diseases, and studying the alarmin pathway in various pathological conditions. It enables researchers to evaluate IL-33 blockade strategies in preclinical models and advance understanding of IL-33 biology.
There are currently no reviews for this product.